Back HCV Treatment

HCV Treatment

FDA Grants Priority Review for Gilead's Sofosbuvir + Ledipasvir Coformulation

The U.S. Food and Drug Administration (FDA) has agreed to expedited review of Gilead Science's sofosbuvir plus ledipasvir coformulation for treatment of chronic hepatitis C, putting the combination pill on track for an approval decision by mid-October, the company recently announced.

alt

Read more:

APASL: Simeprevir Matches Telaprevir in Phase 3 Study, Gets Positive European Regulatory Opinion

The new hepatitis C virus (HCV) protease inhibitor simeprevir has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization in the European Union, Janssen R&D announced this week. The recommendation was based on findings from a set of Phase 3 trials, some of which were presented at the Asian Pacific Association for the Study of the Liver (APASL) conference this month in Brisbane.

alt

Read more:

CROI 2014: Interferon-free BMS Combo Cures 90% of Genotype 1 Hepatitis C

An all-oral regimen of daclatasvir, asunaprevir, and BMS-791325 -- without interferon or ribavirin -- led to sustained response in approximately 90% of previously untreated hepatitis C patients, most with hard-to-treat genotype 1a, according to a study presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.

alt

Read more:

Advances in Hepatitis C Treatment: the Future Is Now [VIDEO]

As effective direct-acting antiviral drugs to treat hepatitis C come into widespread use and interferon-free therapy becomes a reality, patients, providers, and payers are now grappling with issues such as who should receive treatment and how to pay for the new medications.

alt

Read more:

CROI 2014/APASL 2014: Merck Combo Suppresses HCV in Monoinfected and Coinfected Patients

An all-oral combination of the HCV protease inhibitor MK-5172 and the NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in HIV/HCV coinfected patients and high cure rates in people with hepatitis C alone, according to findings from the C-WORTHY study presented at recent conferences.

alt

Read more: